Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Down 6.8% on Analyst Downgrade

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) fell 6.8% during mid-day trading on Friday after Barclays lowered their price target on the stock from $58.00 to $56.00. Barclays currently has an overweight rating on the stock. Collegium Pharmaceutical traded as low as $45.58 and last traded at $45.47. 144,903 shares changed hands during mid-day trading, a decline of 70% from the average session volume of 477,033 shares. The stock had previously closed at $48.78.

COLL has been the topic of a number of other reports. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Truist Financial set a $55.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday. Needham & Company LLC lifted their price target on shares of Collegium Pharmaceutical from $48.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a report on Monday, December 29th. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $52.80.

Insider Transactions at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 30,000 shares of Collegium Pharmaceutical stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the transaction, the chief financial officer directly owned 126,667 shares in the company, valued at approximately $5,133,813.51. The trade was a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the business’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the sale, the director directly owned 52,629 shares of the company’s stock, valued at $2,475,141.87. This represents a 6.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 51,250 shares of company stock worth $2,235,352 in the last 90 days. 2.51% of the stock is currently owned by insiders.

Collegium Pharmaceutical News Summary

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Collegium issued 2026 financial guidance that topped consensus on revenue. Management expects product revenues of $805M–$825M (vs. consensus ~$782.9M) and adjusted EBITDA of $455M–$475M; Jornay PM net revenue is guided to $190M–$200M. This stronger-than-expected top‑line and profitability outlook is a clear positive catalyst. Collegium Provides 2026 Financial Guidance and Business Update
• Positive Sentiment: Needham raised its price target from $48 to $56 and maintained a “buy” rating, implying roughly 23% upside from the current level — a supportive analyst endorsement that can attract buyers. Benzinga TickerReport
• Neutral Sentiment: Barclays trimmed its price target slightly (from $58 to $56) but kept an “overweight” rating — a mixed signal that reduces upside expectations a bit while still indicating conviction in the name. Benzinga
• Neutral Sentiment: A broader industry piece highlighting branded pharmaceuticals and peer Q3 results mentions the group context for names like Collegium; useful for benchmarking but not specific company news. MSN: Branded pharmaceuticals stocks Q3 results
• Negative Sentiment: Zacks downgraded Collegium from “strong-buy” to “hold,” which may prompt some profit‑taking or limit fresh inflows from investors who follow Zacks ratings. Zacks TickerReport

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in COLL. Rubric Capital Management LP lifted its holdings in Collegium Pharmaceutical by 5.3% during the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after purchasing an additional 157,743 shares in the last quarter. Emerald Advisers LLC raised its position in shares of Collegium Pharmaceutical by 1.3% during the 2nd quarter. Emerald Advisers LLC now owns 837,549 shares of the specialty pharmaceutical company’s stock valued at $24,766,000 after purchasing an additional 11,074 shares during the period. Geode Capital Management LLC lifted its stake in shares of Collegium Pharmaceutical by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 780,243 shares of the specialty pharmaceutical company’s stock valued at $23,075,000 after buying an additional 14,709 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after buying an additional 461,914 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in Collegium Pharmaceutical by 13.8% in the 2nd quarter. Bank of America Corp DE now owns 514,807 shares of the specialty pharmaceutical company’s stock worth $15,223,000 after buying an additional 62,274 shares during the period.

Collegium Pharmaceutical Price Performance

The stock has a 50 day simple moving average of $46.23 and a 200-day simple moving average of $38.54. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. The firm has a market cap of $1.44 billion, a PE ratio of 28.29 and a beta of 0.60.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share for the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The company had revenue of $135.55 million during the quarter. Equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.